Products
Torudokimab Biosimilar Monoclonal Antibody (IL-33) for Research
Pre-Made Torudokimab biosimilar, Whole mAb, Anti-IL33 Antibody: Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-588-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Torudokimab biosimilar, Whole mAb, Anti-IL33 Antibody: Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV therapeutic antibody |
| INN Name | Torudokimab |
| Target | IL33 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Eli Lilly |
| Conditions Approved | na |
| Conditions Active | Atopic dermatitis |
| Conditions Discontinued | na |
| Development Tech | na |
About target - IL33
1. Protein Interleukin-33
2. Gene IL33
3. Organism Homo sapiens (Human)
Function
Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells (PubMed:16286016).
Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts as a chemoattractant for Th2 cells, and may function as an 'alarmin', that amplifies immune responses during tissue injury (PubMed:17853410, PubMed:18836528).
In quiescent endothelia the uncleaved form is constitutively and abundantly expressed, and acts as a chromatin-associated nuclear factor with transcriptional repressor properties, it may sequester nuclear NF-kappaB/RELA, lowering expression of its targets (PubMed:21734074).
This form is rapidely lost upon angiogenic or proinflammatory activation (PubMed:18787100).
